IMGT (XKRX:456570) Accounts Receivable : ₩0.00 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is IMGT Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. IMGT's accounts receivables for the quarter that ended in Dec. 2023 was ₩0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. IMGT's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. IMGT's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was ₩-4,049.56.

IMGT Accounts Receivable Historical Data

The historical data trend for IMGT's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IMGT Accounts Receivable Chart

IMGT Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

IMGT Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Accounts Receivable	-	-	-	-

IMGT Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

IMGT Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

IMGT's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	42.4	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), IMGT's accounts receivable are only considered to be worth 75% of book value:

IMGT's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(7918.649	+	0.75 * 0	+	0.5 * 0	-	27417.176
-	0	-	0)	/	4.81497
=	-4,049.56

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

IMGT Accounts Receivable Related Terms

Thank you for viewing the detailed overview of IMGT's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

IMGT (XKRX:456570) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IMGT Corp Ltd (XKRX:456570) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

172 Dolma-ro,, 408, Healthcare Innovation Park, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13605

Website

http://www.imgt.co.kr

IMGT Corp Ltd develops a focused ultrasound-based drug delivery platform for intractable diseases. It is developing nanomedicines and focused ultrasound medical devices that respond to focused ultrasound. The firm has two pipeline products IMD20 and IMP101. IMD20 is a FUS device developed for chronic pain as a product with reduced size and output from IMD10 developed for cancer treatment. IMP101 is a nanoparticle used for hepatocarcinoma embolization.

IMGT (XKRX:456570) Headlines

No Headlines